VRDN Viridian Therapeutics Inc

Simplify Asset Management Inc. has acquired a new position of 50,000 shares in Viridian Therapeutics (NASDAQ:VRDN) during the third quarter, valued at approximately $1.08 million, representing about 0.06% of the company. Other institutional investors like Commodore Capital LP, Maverick Capital Ltd., and Geode Capital Management LLC also adjusted their stakes. Analysts maintain a "Moderate Buy" consensus rating for Viridian Therapeutics with a target price of $41.75, following a significant revenue beat and smaller-than-expected loss per share in their latest earnings report.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has received a "Moderate Buy" consensus rating from thirteen brokerages, with an average 12-month price target of $41.75. The company recently reported better-than-expected quarterly earnings, though it remains unprofitable. Insider and institutional buying activity has increased, with major funds like Fairmount Funds and Wellington Management Group significantly raising their stakes.

Rice Hall James & Associates LLC significantly increased its stake in Viridian Therapeutics (NASDAQ:VRDN) by 65.2% in the third quarter, acquiring 336,040 additional shares. This institutional investor now holds 851,663 shares valued at approximately $18.38 million. The increase follows Viridian Therapeutics' strong quarterly results, which surpassed analyst expectations for both EPS and revenue, and a "Moderate Buy" consensus rating from analysts with an average target price of $41.75.

This article details recent analyst ratings for several healthcare companies. Viridian Therapeutics (VRDN) received a "Strong Buy" consensus with a significant upside, while Fortrea Holdings Inc. (FTRE) garnered a "Hold" consensus with a projected downside. Cytokinetics (CYTK) also received a "Strong Buy" consensus from analysts, indicating a substantial potential upside.

Needham & Company LLC has raised its price target for Viridian Therapeutics (NASDAQ:VRDN) to $42.00 from $34.00, maintaining a "buy" rating, indicating a potential upside of 29.35%. This update follows an earnings beat by Viridian, with EPS of ($0.34) versus an estimated ($0.82) and revenue of $70.57 million against an estimated $16.21 million. The company has a "Moderate Buy" consensus rating from analysts, with an average price target of $41.75, and recently saw significant insider buying.

William Blair analyst Lachlan Hanbury Brown has reiterated a "Buy" rating for Viridian Therapeutics (VRDN) due to its lead program, veligrotug, becoming de-risked. The FDA's acceptance of the biologics license application, along with priority review and a PDUFA date of June 30, 2026, signals strong regulatory confidence. Robust Phase III data showing significant efficacy in thyroid eye disease and convenience advantages over existing treatments further support the positive outlook, suggesting Viridian's shares are currently undervalued.